Impact of Mavacamten on Disease-Related Symptoms in Patients With Obstructive Hypertrophic Cardiomyopathy: HCMSQ Outcomes in EXPLORER-HCM
Authors:
- 6 June 2026
- journal article
- Published by Elsevier in Journal of Cardiac Failure
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
This publication has 15 references indexed in Scilit:
- Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal ReductionJACC, 2024
- 2023 ESC Guidelines for the management of cardiomyopathiesEuropean Heart Journal, 2023
- Longitudinal Psychometric Analysis of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Using Outcomes from the Phase III EXPLORER-HCM TrialPharmacoEconomics - Open, 2022
- Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) InstrumentPharmacoEconomics - Open, 2022
- Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic CardiomyopathyJACC, 2021
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2021
- 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive SummaryJACC, 2020
- Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2020
- New Perspectives on the Prevalence of Hypertrophic CardiomyopathyJACC, 2015
- An Assessment of Clinically Useful Measures of the Consequences of TreatmentNew England Journal of Medicine, 1988